Show simple item record

dc.contributor.authorMattingly, T Joseph
dc.contributor.authorWeathers, Shannon
dc.date.accessioned2022-08-15T13:24:43Z
dc.date.available2022-08-15T13:24:43Z
dc.date.issued2022-07-21
dc.identifier.urihttp://hdl.handle.net/10713/19574
dc.description.abstractCost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates. The complexity of the pharmaceutical supply chain and contractual relationships between manufacturers, wholesalers, pharmacies and payers create challenges for researchers attempting to include drug costs in COI analyses. This article aims to provide contextual information for a general audience interested in conducting or evaluating COI studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.en_US
dc.description.urihttps://doi.org/10.7573/dic.2022-5-4en_US
dc.language.isoenen_US
dc.publisherBioexcel Publishing Ltd.en_US
dc.relation.ispartofDrugs in Contexten_US
dc.rightsCopyright © 2022 Mattingly II TJ, Weathers S.en_US
dc.subjectburden-of-illnessen_US
dc.subjectcost-of-illnessen_US
dc.subjectdrug costsen_US
dc.subjectpharmacoeconomicsen_US
dc.titleDrug costs in context: assessing drug costs in cost-of-illness analyses.en_US
dc.typeArticleen_US
dc.identifier.doi10.7573/dic.2022-5-4
dc.identifier.pmid35949272
dc.source.journaltitleDrugs in context
dc.source.volume11
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record